HBM Group

Harbour BioMed is a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in oncology and immunology. The company leverages its proprietary Harbour Mice platforms to generate fully human monoclonal antibodies, including heavy chain only antibodies (HCAb) and bispecific antibodies. Its lead assets include batoclimab, a potential best-in-class FcRn inhibitor, and tanfanercept, a TNF-alpha inhibitor for ophthalmic diseases. Harbour BioMed operates a platform-driven business model, engaging in numerous strategic partnerships with global pharmaceutical companies to co-develop and out-license its innovative candidates. Through its subsidiary Nona Biosciences, the company also provides antibody discovery services to the broader biotech industry.